Mitazalimab, CAS 2055640-86-1

Product Description: Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Deronic A, et al. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. /[2]Smith K E, et al. Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells[J]. Cancer Research, 2022, 82(12_Supplement): 4155-4155.

CAS Number: 2055640-86-1

Molecular Weight: N/A

Compound Purity: 98.74

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: TNF Receptor

• Artikelnummer: MEXHY-P99742-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99742-5
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated